Last October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn’t cost-effective. So Lilly dished up a new price break—and now the National Institute for Health and Care Excellence (NICE) is on board. The problem, initially, was that Lilly couldn’t provide evidence that Verzenio… Read More »
(Reuters) – A divided Pennsylvania Supreme Court ruled on Friday that mothers who use illegal drugs during their pregnancies are not committing child abuse against their newly-born children. Reversing a lower court ruling, the 5-2 decision came amid a nationwide opioid crisis, including abuse by pregnant women that can result in preterm labor, stillbirth and… Read More »
(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s website showed on Friday. The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely. Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila… Read More »
In today’s world, there is basically a drug prescription for every ailment, from a sore throat to a broken ankle. We have been trained to turn to prescriptions for pain relief. In many cases, prescription drugs are the right option. But in some cases, they are not immediately necessary, especially with more minor injuries and… Read More »
Please enable cookies on your web browser in order to continue. The new European data protection law requires us to inform you of the following before you use our website: We use cookies and other technologies to customize your experience, perform analytics and deliver personalized advertising on our sites, apps and newsletters and across the… Read More »
November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »